HUMIRA® (adalimumab) | Healthcare Professional Site
Safety Data | Active Psoriatic Arthritis | HUMIRA® (adalimumab)
Safety Data | Active Ankylosing Spondylitis | HUMIRA® (adalimumab)
Psoriatic Arthritis HUMIRA (adalimumab) Dosing Information
How Big Is The Biosimilar Threat To AbbVie's Humira? (NYSE:ABBV) | Seeking Alpha
Humira Label Updated With Fingernail Psoriasis Data - MPR
Safety Data | Moderate to Severe Rheumatoid Arthritis | HUMIRA® (adalimumab)
Amgevita (adalimumab) for Rheumatoid Arthritis | Amgen
European Commission approves HUMIRA's label update
Humira - FDA prescribing information, side effects and uses
Adalimumab - wikidoc
Adalimumab - wikidoc
Adalimumab - wikidoc
Safety | Crohn's Disease (CD) | HUMIRA® (adalimumab)
2020HumiraGrid.jpg
Adalimumab - wikidoc
Taking Citrate-Free Humira: What Patients Need to Know
HUMIRA (adalimumab) for the Treatment of Ulcerative Colitis
Humira 40 mg/0.4 ml Pre-filled Syringe and Pre-filled Pen (Great Britain) - Summary of Product Characteristics (SmPC) - (emc)
Adalimumab - wikidoc
These highlights do not include all the information needed to use IMRALDI safely and effectively. See full prescribing information for IMRALDI.IMRALDI (adalimumab-xxxx) injection, for subcutaneous useInitial U.S. Approval: YYYY IMRALDI (adalimumab-xxxx) is
NDC 0074-0817 Humira Adalimumab
